UNCY
Unicycive Therapeutics, Inc. NASDAQ Listed Jul 12, 2021$7.86
Pre-mkt
$8.39
+2.69%
Mkt Cap $168.9M
52w Low $3.71
56.9% of range
52w High $11.00
50d MA $6.98
200d MA $5.66
P/E (TTM)
-4.6x
EV/EBITDA
-34.3x
P/B
40.4x
Debt/Equity
0.0x
ROE
-87.9%
P/FCF
-29.2x
RSI (14)
—
ATR (14)
—
Beta
1.80
50d MA
$6.98
200d MA
$5.66
Avg Volume
530.7K
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
4300 El Camino Real · Los Altos, CA 94022 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.50 | -0.32 | +36.6% | 6.11 | +1.8% | +7.7% | +8.2% | -2.7% | -4.5% | +0.9% | — |
| Nov 12, 2025 | AMC | -0.59 | -0.39 | +33.9% | 5.14 | +0.2% | +3.7% | +6.4% | +1.8% | +2.6% | -6.6% | — |
| Aug 14, 2025 | AMC | -0.70 | -0.52 | +25.7% | 4.63 | -0.4% | +1.5% | -13.2% | -0.2% | +0.5% | +3.9% | — |
| Mar 31, 2025 | AMC | -0.13 | -0.26 | -100.0% | 5.75 | +4.3% | -5.0% | +0.5% | +7.5% | -12.5% | -10.7% | — |
| Mar 27, 2025 | AMC | -0.13 | -0.16 | -23.1% | 6.26 | -0.8% | -1.9% | -6.4% | -5.0% | +0.5% | +7.5% | — |
| Aug 14, 2024 | AMC | -0.23 | -0.15 | +34.8% | 3.16 | -3.5% | -5.1% | +3.0% | +21.4% | +5.1% | -4.6% | — |
| May 13, 2024 | AMC | -0.18 | -0.27 | -50.0% | 10.90 | +6.4% | +0.0% | -0.9% | -4.6% | +1.0% | +1.9% | — |
| Mar 28, 2024 | AMC | -0.18 | -0.16 | +11.1% | 13.80 | +0.7% | +2.2% | -2.1% | -0.7% | +6.6% | -2.7% | — |
| Nov 14, 2023 | AMC | -0.13 | -0.13 | +0.0% | 5.19 | -1.0% | +0.8% | -1.9% | -1.9% | +3.4% | -3.5% | — |
| Aug 14, 2023 | AMC | -0.39 | -0.29 | +25.6% | 8.21 | -3.0% | -7.4% | +7.8% | -2.0% | +0.7% | +1.2% | — |
| May 16, 2023 | AMC | -0.36 | -0.29 | +19.4% | 13.70 | -2.2% | +2.2% | -0.7% | -0.7% | -0.7% | +2.2% | — |
| Mar 31, 2023 | AMC | 0.24 | -0.35 | -245.8% | 21.00 | +3.3% | +6.2% | -2.2% | -2.3% | -2.8% | +0.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | B. Riley Securities | Initiates | Buy | $22 | $7.66 | $7.80 | +1.8% | +0.1% | +4.0% | +1.3% | +0.6% | -3.3% |
| Apr 6 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $6.93 | $6.95 | +0.3% | -4.5% | +0.9% | -3.4% | +3.1% | -0.3% |
| Apr 2 | Guggenheim | Maintains | Buy → Buy | — | $7.12 | $6.95 | -2.4% | -2.7% | -4.5% | +0.9% | -3.4% | +3.1% |
| Oct 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.72 | $4.81 | +1.9% | +1.7% | +0.2% | -1.2% | -6.5% | +0.0% |
| Sep 15 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $3.87 | $3.87 | +0.0% | +1.8% | +1.3% | +1.3% | +1.2% | -3.2% |
| Apr 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.30 | $5.35 | +0.9% | +3.4% | +11.3% | -2.6% | +0.7% | +0.3% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.75 | $6.00 | +4.3% | -5.0% | +0.5% | +7.5% | -12.5% | -10.7% |
| Jan 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.39 | $5.30 | -1.7% | -1.7% | +9.4% | +5.9% | -2.3% | +0.2% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.78 | $7.80 | +0.3% | -4.2% | -10.9% | +3.3% | -3.6% | +1.4% |
| Nov 22 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $5.28 | $5.28 | +0.0% | +0.4% | +4.3% | +6.7% | +14.9% | +1.6% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.78 | $4.78 | +0.0% | -6.3% | +2.7% | -1.1% | +6.6% | +4.9% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.33 | $5.30 | -0.6% | -9.2% | -1.2% | -6.3% | +2.7% | -1.1% |
| Oct 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.60 | $3.69 | +2.5% | +0.6% | -0.8% | +3.1% | +4.6% | +3.4% |
| Sep 6 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $3.53 | $3.60 | +2.0% | +0.3% | +4.8% | +5.4% | +2.3% | -5.0% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.38 | $3.33 | -1.5% | -5.9% | +6.3% | +4.4% | +0.3% | +4.8% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.16 | $3.05 | -3.5% | -5.1% | +3.0% | +21.4% | +5.1% | -4.6% |
| Jul 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.76 | $4.70 | -1.3% | +2.1% | -1.2% | +3.1% | +0.8% | -5.4% |
| Jun 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.83 | $6.29 | -7.9% | -26.8% | -4.0% | -15.6% | +23.7% | +7.8% |
| Jun 3 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $8.80 | $9.00 | +2.3% | +3.0% | -11.0% | -3.2% | -1.3% | +0.8% |
| May 31 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $8.37 | $8.45 | +1.0% | +5.1% | +3.0% | -11.0% | -3.2% | -1.3% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.36 | $8.40 | +0.5% | +0.5% | -0.4% | +5.1% | +3.0% | -11.0% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.90 | $11.60 | +6.4% | +0.0% | -0.9% | -4.6% | +1.0% | +1.9% |
| Apr 15 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $12.20 | $12.20 | +0.0% | -6.6% | -1.8% | +3.6% | -6.0% | -1.8% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.80 | $13.90 | +0.7% | +2.2% | -2.1% | -0.7% | +6.6% | -2.7% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.90 | $15.10 | +8.6% | +3.6% | +1.4% | -2.1% | -2.8% | +2.2% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.00 | $14.00 | -6.7% | +1.3% | -2.0% | -4.0% | -2.8% | +3.6% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.90 | $15.10 | +1.3% | -1.3% | +4.1% | -2.0% | +1.3% | -2.0% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.90 | $6.13 | +3.9% | +1.5% | -4.0% | -0.9% | +1.8% | +3.4% |
| Dec 4 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $4.90 | $5.25 | +7.1% | +0.4% | +11.8% | -3.8% | +9.6% | +6.0% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.60 | $8.04 | +5.8% | +7.8% | -2.0% | +0.7% | +1.2% | -2.9% |
| Jul 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.80 | $12.90 | +0.8% | -2.3% | +0.0% | -2.4% | +0.8% | -1.6% |
| Jun 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.50 | $13.00 | -21.2% | -22.4% | -10.2% | -0.9% | +1.8% | +12.9% |
| Jun 30 | EF Hutton | Maintains | Buy → Buy | — | $16.50 | $13.00 | -21.2% | -22.4% | -10.2% | -0.9% | +1.8% | +12.9% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.90 | $15.00 | +0.7% | +13.4% | -1.8% | +3.0% | -3.5% | -22.4% |
| Jun 23 | Benchmark | Maintains | Speculative Buy → Buy | — | $15.00 | $14.40 | -4.0% | -0.7% | +13.4% | -1.8% | +3.0% | -3.5% |
| Jun 20 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $14.60 | $14.60 | +0.0% | +2.1% | -1.3% | +2.0% | -0.7% | +13.4% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.70 | $13.40 | -2.2% | +2.2% | -0.7% | -0.7% | -0.7% | +2.2% |
| May 17 | EF Hutton | Maintains | Buy → Buy | — | $13.70 | $13.40 | -2.2% | +2.2% | -0.7% | -0.7% | -0.7% | +2.2% |
| Apr 21 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $16.10 | $16.30 | +1.2% | +1.9% | -4.3% | -5.7% | -8.1% | -2.2% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.00 | $21.70 | +3.3% | +6.2% | -2.2% | -2.3% | -2.8% | +0.0% |
| Mar 31 | EF Hutton | Maintains | Buy → Buy | — | $18.80 | $18.50 | -1.6% | +11.7% | +6.2% | -2.2% | -2.3% | -2.8% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.20 | $19.10 | +17.9% | +27.2% | +30.1% | -19.0% | +1.8% | +0.0% |
| Mar 9 | Maxim Group | Maintains | Buy → Buy | — | $16.20 | $19.10 | +17.9% | +27.2% | +30.1% | -19.0% | +1.8% | +0.0% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.70 | $7.16 | +6.9% | -1.5% | +9.1% | -1.1% | +1.8% | -3.4% |
| Jun 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.50 | $11.10 | +5.7% | +1.0% | +0.0% | +0.0% | -7.5% | +0.5% |
| Mar 16 | Maxim Group | Maintains | Buy → Buy | — | $10.70 | $13.80 | +29.0% | +3.7% | -1.8% | +3.7% | +11.5% | +4.0% |
| Aug 9 | Roth Capital | Maintains | Buy → Buy | — | $26.50 | $28.00 | +5.7% | +15.1% | -6.6% | -1.1% | -0.7% | -2.5% |
No insider trades available.
8-K · 2.02
!! High
Unicycive Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of an executive at Unicycive Therapeutics (UNCY), a biotech company, signals potential leadership uncertainty that could impact drug development timelines and investor confidence in near-term milestones.
Apr 6
8-K
Unknown — 8-K Filing
Unicycive's FDA decision on its lead candidate by June 2026 with $54.9M cash provides near-term catalysts, but limited runway into 2027 creates financing risk if approval delays or revenues disappoint post-launch.
Mar 30
Data updated apr 27, 2026 6:48am
· Source: massive.com